<DOC>
	<DOC>NCT02038023</DOC>
	<brief_summary>To determine the percentage of women who achieve anemia correction after a single dose of 1000mg of low molecular weight iron dextran(infed).</brief_summary>
	<brief_title>Intravaneous Iron(1000 mg Low Molecular Weight Iron Dextran Over 60 Minutes) for Pregnant Women</brief_title>
	<detailed_description>To determine the percentage of women who achieve anemia correction after a single dose of 1000mg of low molecular weight iron dextran(infed). To determine whether IV iron supplementation has a higher satisfaction with treatment as compared to oral supplementation in a population previously intolerant of or unresponsive to oral iron. To evaluate the safety of IV low molecular weight iron dextran in pregnant women. To assess maternal and fetal outcomes-preterm delivery, low birth weight deliveries, ER visits and hospitalizations related to preterm labor, preterm contractions, ante-partum and post-partum transfusions, maternal hemoglobin at post-partum visit after IV iron supplementation groups.</detailed_description>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Iron-Dextran Complex</mesh_term>
	<mesh_term>Dextrans</mesh_term>
	<criteria>pregnant women intolerable to oral iron. hbg &lt;10.9 g/dl during second or third trimester. known sensitivity to IV iron. hemoglobinopathies. hemolytic anemia. women who have received or will receive blood transfusions. women with significant vaginal bleeding(&gt;200 cc blood loss)prior to delivery. women with documented history of allergy to more than one class of drug clinically significant anemia requiring therapy in the opinion of the obstetrician, in the first trimester.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Iv iron in pregnant women</keyword>
	<keyword>second and third trimester</keyword>
</DOC>